Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MSB
stocks logo

MSB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Mesabi Trust (MSB.N) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Mesabi Trust 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

MSB News & Events

Events Timeline

(ET)
2024-10-17
16:06:04
Mesabi Trust raises quarterly distribution to 39c per share from 35c
select
2024-09-11 (ET)
2024-09-11
12:00:45
Mesabi Trust rises 27.8%
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-04Globenewswire
Mesoblast Participates in Piper Sandler Healthcare Conference, CEO to Speak
  • Conference Participation: Mesoblast is participating in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, where CEO Silviu Itescu is scheduled for a fireside chat on December 4 at 12:00 PM ET, highlighting the company's leadership in inflammatory diseases.
  • Technology Showcase: The event will feature a live webcast, allowing viewers to access the discussion via a provided link, which enhances the company's visibility and transparency among investors, potentially increasing interest from prospective investors.
  • Product Introduction: Mesoblast's Ryoncil® is the first FDA-approved mesenchymal stem cell therapy for treating steroid-refractory acute graft versus host disease in children, showcasing the company's innovative capabilities in cell therapy.
  • Intellectual Property Protection: Mesoblast holds over 1,000 patents covering its stem cell technology, ensuring commercial protection extending to 2044 in major markets, which strengthens the company's competitive position and long-term growth potential.
[object Object]
Preview
9.5
11-25Newsfilter
Mesoblast Projects Over $30 Million in Quarterly Revenue from Ryoncil
  • Revenue Growth: Mesoblast anticipates gross revenue exceeding $30 million for Ryoncil® in the quarter ending December 31, 2025, representing a more than 37% increase from $21.9 million in the prior quarter, indicating strong market demand for its inflammatory disease treatments.
  • Product Innovation: Ryoncil® is the first FDA-approved mesenchymal stem cell therapy designed for treating steroid-refractory acute graft versus host disease in pediatric patients, highlighting the company's leadership in the cell therapy sector.
  • Global Partnerships: Mesoblast has established commercial partnerships in Japan, Europe, and China, further expanding its global market reach and enhancing its competitive position internationally.
  • Intellectual Property Protection: The company boasts over 1,000 granted patents or applications, ensuring commercial protection for its mesenchymal stem cell technology through at least 2044 in major markets, which strengthens its future market position and profitability.
[object Object]
Preview
8.0
10-11Newsfilter
Mesabi Trust Announces News Release

  • Distribution Announcement: Mesabi Trust declared a distribution of $0.34 per Unit of Beneficial Interest, payable on November 20, 2025, which is a decrease from the $0.39 distribution from the previous year.

  • Factors Influencing Distribution: The Trustees' decision reflects total royalty payments received from Cleveland-Cliffs Inc. and considerations for maintaining reserves to cover current and future expenses amid uncertainties in the iron ore and steel industries.

  • Royalty Payments Timeline: Quarterly royalty payments from Cliffs and Northshore for the third calendar quarter are due on October 30, 2025, and a summary report will be filed with the SEC following receipt.

  • Forward-Looking Statements: The announcement includes forward-looking statements regarding Northshore operations and potential risks that could affect actual production and royalty payments, emphasizing the inherent uncertainties in the industry.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mesabi Trust (MSB) stock price today?

The current price of MSB is 33.57 USD — it has increased 3.32 % in the last trading day.

arrow icon

What is Mesabi Trust (MSB)'s business?

Mesabi Trust is a royalty trust organized to derive income from an iron mine (the Peter Mitchell Mine) located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range. The Trust is a pass-through entity. It operates in one segment, which is iron ore mining. The mine is operated by Northshore Mining Company (Northshore), a subsidiary of Cleveland-Cliffs Inc. (CCI). Northshore mines the ore, which is in the form of taconite, a hard rock containing approximately 21% recoverable iron, crushes it, separates the iron particles from the non-metallic, and forms the resulting concentrate into pellets which are shipped for use in steel-producing blast furnaces of customers of CCI. Northshore pays royalties to the Trust primarily based on the selling price of pellets shipped from Northshore’s pellet plant at Silver Bay, Minnesota, on Lake Superior approximately 45 miles from the mine, plus a significantly smaller royalty based on tons of ore extracted at the mine.

arrow icon

What is the price predicton of MSB Stock?

Wall Street analysts forecast MSB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MSB is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mesabi Trust (MSB)'s revenue for the last quarter?

Mesabi Trust revenue for the last quarter amounts to 4.73M USD, decreased -24.25 % YoY.

arrow icon

What is Mesabi Trust (MSB)'s earnings per share (EPS) for the last quarter?

Mesabi Trust. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Mesabi Trust (MSB)'s fundamentals?

The market is revising No Change the revenue expectations for MSB for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 7.60%.
arrow icon

How many employees does Mesabi Trust (MSB). have?

Mesabi Trust (MSB) has 0 emplpoyees as of December 05 2025.

arrow icon

What is Mesabi Trust (MSB) market cap?

Today MSB has the market capitalization of 229.47M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free